CN105504017A - 一种治疗癌症的肽变体及其应用 - Google Patents
一种治疗癌症的肽变体及其应用 Download PDFInfo
- Publication number
- CN105504017A CN105504017A CN201610002932.9A CN201610002932A CN105504017A CN 105504017 A CN105504017 A CN 105504017A CN 201610002932 A CN201610002932 A CN 201610002932A CN 105504017 A CN105504017 A CN 105504017A
- Authority
- CN
- China
- Prior art keywords
- cancer
- peptide
- carcinoma
- seqidno
- artificialsequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 21
- 201000011510 cancer Diseases 0.000 title claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 201000005619 esophageal carcinoma Diseases 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000008261 skin carcinoma Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 230000022534 cell killing Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101150051106 SWEET11 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
SEQ序列号(XA代号) | 序列 | 氨基酸数目 |
1(XA1) | INWLKIAKKVAGML-NH2 | 14 |
2(XA2) | SINWLKIAKKVAGML-NH2 | 15 |
3(XA3) | SINWLAIAKKVAGML-NH2 | 15 |
4(XA4) | SINWLAIAAKVAGML-NH2 | 15 |
5(XA5) | SINWLAIAAKVGGML-NH2 | 15 |
6(XA6) | SINWLKIAKKVAGMLL-NH2 | 16 |
7(XA7) | SINWLKIAKKVAGMLL-NH2 | 16 |
8(XA8) | SINWLAIAKKVAGMLL-NH2 | 16 |
9(XA9) | SINWLAIAAKVAGMLL-NH2 | 16 |
10(XA10) | SINWLAIAAKVGGMLL-NH2 | 16 |
11(XA11) | INWLINWLKIAKKVAGML-NH2 | 18 |
12(XA12) | INWLSINWLKIAKKVAGML-NH2 | 19 |
13(XA13) | INWLSINWLAIAKKVAGML-NH2 | 19 |
14(XA14) | INWLSINWLAIAAKVGGMLL-NH2 | 201 --> |
15(XA15) | INWLSINWLKIAKKVAGMLL-NH2 | 20 |
16(XA16) | INWL INWLAIAKKVAGML-NH2 | 18 |
17(XA17) | INWLSINWLAIAKKVAGMLL-NH2 | 20 |
组织类型 | 细胞系 |
急性早幼粒细胞白血病细胞系 | NB4 |
肝癌 | HepG2 |
胶质母细胞瘤 | U87M6 |
SEQ序列号(XA代号) | NB4(IC50) | HepG2(IC50) | U87M6(IC50) |
1(XA1) | 52.2 | 35.8 | 15.41 |
2(XA2) | 37.3 | 29.3 | 10.9 |
3(XA3) | 32.5 | 27.4 | 9.8 |
4(XA4) | 34.6 | 25.4 | 10.3 |
5(XA5) | 31.9 | 26.9 | 10.1 |
6(XA6) | 40.1 | 24.8 | 9.7 |
7(XA7) | 34.9 | 28.7 | 9.63 --> |
8(XA8) | 35.2 | 27.3 | 10.0 |
9(XA9) | 37.8 | 28.1 | 10.2 |
10(XA10) | 36.3 | 25.1 | 10.4 |
11(XA11) | 30.9 | 20.9 | 9.9 |
12(XA12) | 29.8 | 19.9 | 9.3 |
13(XA13) | 31.7 | 21.7 | 9.7 |
14(XA14) | 39.5 | 22.5 | 9.7 |
15(XA15) | 28.7 | 20.1 | 10.1 |
16(XA16) | 60.9 | 45.9 | 30.5 |
17(XA17) | 65.3 | 50.5 | 35.7 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610002932.9A CN105504017B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610002932.9A CN105504017B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201410245332.6A CN104031120B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410245332.6A Division CN104031120B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105504017A true CN105504017A (zh) | 2016-04-20 |
CN105504017B CN105504017B (zh) | 2019-05-03 |
Family
ID=51462136
Family Applications (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610002825.6A Active CN105504016B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002932.9A Expired - Fee Related CN105504017B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002930.XA Expired - Fee Related CN105585615B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002912.1A Active CN105601714B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002926.3A Active CN105597078B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002869.9A Active CN105481949B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002824.1A Expired - Fee Related CN105601711B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体xa5及其应用 |
CN201410245332.6A Expired - Fee Related CN104031120B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002822.2A Expired - Fee Related CN105601710B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002827.5A Expired - Fee Related CN105601712B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002834.5A Active CN105481948B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002817.1A Active CN105622722B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体xa3及其应用 |
CN201610002923.XA Expired - Fee Related CN105601715B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002828.XA Expired - Fee Related CN105601713B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610002825.6A Active CN105504016B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
Family Applications After (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610002930.XA Expired - Fee Related CN105585615B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002912.1A Active CN105601714B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002926.3A Active CN105597078B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002869.9A Active CN105481949B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002824.1A Expired - Fee Related CN105601711B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体xa5及其应用 |
CN201410245332.6A Expired - Fee Related CN104031120B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002822.2A Expired - Fee Related CN105601710B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002827.5A Expired - Fee Related CN105601712B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002834.5A Active CN105481948B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002817.1A Active CN105622722B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体xa3及其应用 |
CN201610002923.XA Expired - Fee Related CN105601715B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
CN201610002828.XA Expired - Fee Related CN105601713B (zh) | 2014-05-29 | 2014-05-29 | 一种治疗癌症的肽变体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (14) | CN105504016B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276477A (zh) * | 2018-03-29 | 2018-07-13 | 张建华 | 一种治疗癌症的合成多肽及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102971336A (zh) * | 2010-05-27 | 2013-03-13 | 埃斯泰·苏济·阿莱特·费卢 | 用作药物、特别是用于治疗癌症的肽 |
CN103265621A (zh) * | 2013-05-30 | 2013-08-28 | 苏州普罗达生物科技有限公司 | 一种微管蛋白解聚剂多肽及其应用 |
CN103288926A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 一种微管蛋白聚合剂多肽及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU219813B (hu) * | 1993-06-30 | 2001-08-28 | Pharmacia S.P.A. | Mitogenezis és motogenezis peptid inhibitorok |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
-
2014
- 2014-05-29 CN CN201610002825.6A patent/CN105504016B/zh active Active
- 2014-05-29 CN CN201610002932.9A patent/CN105504017B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201610002930.XA patent/CN105585615B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201610002912.1A patent/CN105601714B/zh active Active
- 2014-05-29 CN CN201610002926.3A patent/CN105597078B/zh active Active
- 2014-05-29 CN CN201610002869.9A patent/CN105481949B/zh active Active
- 2014-05-29 CN CN201610002824.1A patent/CN105601711B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201410245332.6A patent/CN104031120B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201610002822.2A patent/CN105601710B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201610002827.5A patent/CN105601712B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201610002834.5A patent/CN105481948B/zh active Active
- 2014-05-29 CN CN201610002817.1A patent/CN105622722B/zh active Active
- 2014-05-29 CN CN201610002923.XA patent/CN105601715B/zh not_active Expired - Fee Related
- 2014-05-29 CN CN201610002828.XA patent/CN105601713B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102971336A (zh) * | 2010-05-27 | 2013-03-13 | 埃斯泰·苏济·阿莱特·费卢 | 用作药物、特别是用于治疗癌症的肽 |
CN103265621A (zh) * | 2013-05-30 | 2013-08-28 | 苏州普罗达生物科技有限公司 | 一种微管蛋白解聚剂多肽及其应用 |
CN103288926A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 一种微管蛋白聚合剂多肽及其应用 |
Non-Patent Citations (1)
Title |
---|
王翠翠等: "文蛤多肽抑制肿瘤细胞微管蛋白聚合", 《中国生化药物杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105601712A (zh) | 2016-05-25 |
CN105601715B (zh) | 2019-10-01 |
CN105585615B (zh) | 2019-11-15 |
CN105601713B (zh) | 2019-10-22 |
CN105481948B (zh) | 2019-12-27 |
CN105481949B (zh) | 2019-11-12 |
CN104031120A (zh) | 2014-09-10 |
CN104031120B (zh) | 2016-08-24 |
CN105601710B (zh) | 2019-10-15 |
CN105504016B (zh) | 2019-01-01 |
CN105601713A (zh) | 2016-05-25 |
CN105481949A (zh) | 2016-04-13 |
CN105481948A (zh) | 2016-04-13 |
CN105504017B (zh) | 2019-05-03 |
CN105585615A (zh) | 2016-05-18 |
CN105622722B (zh) | 2019-12-24 |
CN105601711B (zh) | 2019-11-05 |
CN105601715A (zh) | 2016-05-25 |
CN105504016A (zh) | 2016-04-20 |
CN105597078A (zh) | 2016-05-25 |
CN105601712B (zh) | 2019-10-11 |
CN105601711A (zh) | 2016-05-25 |
CN105601714B (zh) | 2019-09-13 |
CN105601710A (zh) | 2016-05-25 |
CN105597078B (zh) | 2019-01-25 |
CN105601714A (zh) | 2016-05-25 |
CN105622722A (zh) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102971336B (zh) | 用作药物、特别是用于治疗癌症的肽 | |
AU727662B2 (en) | Peptides having antiproliferative properties | |
CN102037005B (zh) | 改善治疗功效的新光学纯化合物 | |
JP2008519785A (ja) | 高められた細胞取り込み活性を有する結合体 | |
EP4316503A1 (en) | Pharmaceutical use of cyclic peptide compound | |
CN101597326A (zh) | kahalalide F及相关化合物 | |
CN105524142B (zh) | 一种十六肽qtddnhsnvlwagfsr及其应用 | |
CN105504017A (zh) | 一种治疗癌症的肽变体及其应用 | |
JP2010509241A5 (zh) | ||
CN109503701A (zh) | 一种环肽及其在制备抗肿瘤药物中的应用 | |
JP6872713B2 (ja) | 腫瘍細胞の放射線感受性を増大させる合成ペプチド及びその利用 | |
Wu et al. | Total synthesis and modification of proline-rich cyclopeptides Phakellistatins 17 and 18 isolated from marine sponge | |
CN110117324A (zh) | 一种抗肿瘤活性多肽及其用途 | |
CN105175496B (zh) | 一种七肽pgkplfl及其应用 | |
CN108299556B (zh) | 一种治疗血液肿瘤的多肽 | |
Darwish et al. | Efficient synthesis of CN2097 using in situ activation of sulfhydryl group | |
Rajesh et al. | Recent advances in the synthesis of some bioactive peptides and peptidomimetics | |
RU2786528C1 (ru) | Средство, снижающее относительное содержание низкодифференцированных и повышающее относительное содержание высокодифференцированных клеток в инвазивной карциноме молочной железы неспецифического типа | |
CN105153283B (zh) | 一种八肽sccscded及其应用 | |
WO2007009317A2 (fr) | Medicament peptidique inhibiteur des tumeurs solides et des cellules cancereuses de la leucemie | |
CN105936642A (zh) | 具有抑制癌细胞生长活性的肽及其应用 | |
CN105936643A (zh) | 具有抑制癌细胞生长活性的肽及其应用 | |
CN106167513A (zh) | 具有抑制癌细胞生长活性的肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190102 Address after: 300 000 No. 241 Weijin Road, Hexi District, Tianjin Applicant after: Zhu Changjun Address before: 100073 11 Taiping Bridge District, Fengtai District, Beijing 905 Applicant before: Zhu Lingwei |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190111 Address after: Room 213-03 on the second floor of Block D of Nangang Industrial Zone Office Building, Tianjin Binhai New Area Economic and Technological Development Zone, Tianjin (No. 649 of Tianjin Xinxing Business Secretary Service Co., Ltd.) Applicant after: TIANJIN JIUYI BIOLOGICAL TECHNOLOGY CO.,LTD. Address before: 300 000 No. 241 Weijin Road, Hexi District, Tianjin Applicant before: Zhu Changjun |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190416 Address after: 300 000 No. 241 Weijin Road, Hexi District, Tianjin Applicant after: Zhu Changjun Address before: Room 213-03 on the second floor of Block D of Nangang Industrial Zone Office Building, Tianjin Binhai New Area Economic and Technological Development Zone, Tianjin (No. 649 of Tianjin Xinxing Business Secretary Service Co., Ltd.) Applicant before: TIANJIN JIUYI BIOLOGICAL TECHNOLOGY CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190919 Address after: Room 109, Building 5, No. 4, Haitai Development Road, No. 2, Huayuan Industrial Zone, Tianjin Binhai New Area, 300450 Patentee after: TIANJIN MAITUOSI BIOTECHNOLOGY Co.,Ltd. Address before: 300 000 No. 241 Weijin Road, Hexi District, Tianjin Patentee before: Zhu Changjun |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200319 Address after: Room 213-03, floor 2, building D, comprehensive service area, Nangang Industrial Zone, economic and Technological Development Zone, Binhai New Area, Tianjin 300000 (trusteeship No. 649, Tianjin Xinxing Business Secretary Service Co., Ltd.) Patentee after: TIANJIN JIUYI BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: Room 109, Building 5, No. 4, Haitai Development Road, No. 2, Huayuan Industrial Zone, Tianjin Binhai New Area, 300450 Patentee before: TIANJIN MAITUOSI BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190503 |
|
CF01 | Termination of patent right due to non-payment of annual fee |